Down-regulation of frizzled-7 expression decreases survival, invasion and metastatic capabilities of colon cancer cells. by Ueno, K et al.
UCSF
UC San Francisco Previously Published Works
Title
Down-regulation of frizzled-7 expression decreases survival, invasion and metastatic 
capabilities of colon cancer cells.
Permalink
https://escholarship.org/uc/item/4sg7r5z4
Journal
British journal of cancer, 101(8)
ISSN
0007-0920
Authors
Ueno, K
Hazama, S
Mitomori, S
et al.
Publication Date
2009-10-01
DOI
10.1038/sj.bjc.6605307
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Down-regulation of frizzled-7 expression decreases survival,
invasion and metastatic capabilities of colon cancer cells
K Ueno1, S Hazama2, S Mitomori1, M Nishioka1, Y Suehiro1, H Hirata3, M Oka2, K Imai4, R Dahiya3 and
Y Hinoda*,1
1Department of Oncology and Laboratory Medicine, Yamaguchi University Graduate School of Medicine, Ube, Japan; 2Department of Surgery II,
Yamaguchi University Graduate School of Medicine, Ube, Japan; 3Department of Urology, Veterans Affairs Medical Center and University of California
at San Francisco, San Francisco, CA, USA; 4Sapporo Medical University, Sapporo, Japan
BACKGROUND: The canonical Wnt signalling pathway is activated in most sporadic colorectal cancers (CRCs). We previously reported
that FZD7 functions as a receptor for the canonical Wnt signalling pathway in colon cancer cells.
METHODS AND RESULTS: In this study, we examined the function of FZD7 in survival, invasion and metastatic capabilities of colon cancer
cells. FZD7_siRNA transfection decreased cell viability of HT-29 and HCT-116 colon cancer cells. Expression of c-Jun,
phosphorylation of JNK and c-Jun, and activation of RhoA were suppressed after FZD7_siRNA transfection into HCT-116 cells.
In vitro invasion activity and Wnt target gene expression were also reduced in HCT-116 cells transfected with FZD7_siRNA. Liver
metastasis of stable FZD7_siRNA HCT-116 cell transfectants in scid mice was decreased to 40–50% compared to controls. The
mRNA levels of FZD7 in 135 primary CRC tissues were examined by real-time PCR. FZD7 mRNA levels were significantly higher
in stage II, III or IV tumours than in non-tumour tissues (Po0.005), and overall survival was shorter in those patients with higher
FZD7 expression (Po0.001).
CONCLUSION: These data suggest that FZD7 may be involved in enhancement of survival, invasion and metastatic capabilities of colon
cancer cells through non-canonical Wnt signalling pathways as well as the canonical pathway.
British Journal of Cancer (2009) 101, 1374–1381. doi:10.1038/sj.bjc.6605307 www.bjcancer.com
Published online 22 September 2009
& 2009 Cancer Research UK
Keywords: frizzled-7; siRNA; colorectal cancer; metastasis; RhoA



















































The Wnt signalling pathway is composed of canonical and non-
canonical signals. The canonical Wnt signalling pathway that
regulates cell fate and proliferation is initiated by binding of Wnt
ligands to frizzled transmembrane receptors, and low-density
lipoprotein receptor-related proteins. b-Catenin associates with
T-cell factor (Tcf)/lymphocyte enhancer transcription factors to
activate target genes that are related to cell survival, proliferation
and invasion (Moon et al, 2004; Clevers, 2006). The non-canonical
Wnt signalling pathway consists of Wnt/Ca2þ pathway and
Wnt/c-Jun N-terminal kinase (JNK) (planar cell polarity) path-
way (Cohen et al, 2008). In the Wnt/Ca2þ pathway, Wnt activates
intracellular Ca2þ signalling, as well as Ca2þ -dependent protein
kinases, such as protein kinase C (PKC) and calmodulin-
dependent protein kinase II. In the Wnt/JNK pathway, receptor
stimulation activates Dishevelled (Dvl), which in turn activates
Rho family of GTPases such as RhoA and Rac. RhoA stimulates
c-Jun expression through phosphorylation of c-Jun by Rho-
associated kinase (ROCK) (Marinissen et al, 2004). Accumulating
evidence suggests that non-canonical Wnt signalling is important
in regulating cell polarity and movement (Veeman et al, 2003).
It is well known that the canonical Wnt signalling pathway
is activated in most sporadic colorectal cancers (CRCs; B80%),
which is mainly caused by mutations in the adenomatous
polyposis coli (APC) gene (Segditsas and Tomlinson, 2006;
Schneikert and Behrens, 2007). In a small proportion of cases
(B10%), activated mutations of the b-catenin gene (CTNNB1) are
found (Schneikert and Behrens, 2007). However, recent findings
revealed that Wnt ligands or inhibitors could affect the growth and
survival of colon cancer cells in spite of the presence of APC or
CTNNB1 mutations (Bafico et al, 2004; Suzuki et al, 2004; He et al,
2005). These findings suggested that Wnt ligands and receptors
that function upstream of APC might have a vital role in the
development of CRCs.
We have recently reported that frizzled-7 (FZD7), 1 of 10
members of the FZD gene family, is predominantly expressed in
colon cancer cells and is implicated in canonical Wnt signalling in
colon cancer cells with APC or CTNNB1 mutations (Ueno et al,
2008). Moreover, the down-regulation of FZD7 with Small-inter-
fering RNA (siRNA) in colon cancer cells resulted in decreased in
vitro invasion activity (Ueno et al, 2008), which is consistent
with previous findings that inhibition of FZD7 expression with
dominant-negative mutant construct or siRNA reduced the
motility of hepatocellular carcinoma cells (Merle et al, 2004) or
colon cancer cells (Vincan et al, 2007), respectively. These data
suggest that FZD7 may be important in the invasion and metastasis
of CRC. Recent studies have shown that non-canonical Wnt
signalling pathways affect the motility and invasion of cancer cells
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(Weeraratna et al, 2002; Croft et al, 2004; Qiang et al, 2005), but
there is little data on CRC cells. Although there is a report that
conditional ROCK activation of colon cancer cells induced in vitro
motility and in vivo tumour cell dissemination in nude mice (Croft
et al, 2004), the relation of FZD7 with non-canonical signals in
CRC cells remains unknown.
In this study, we hypothesised that FZD7 may be involved in
progression of CRC probably through both canonical and non-
canonical signalling pathways. To address this hypothesis, we
attempted to reveal a function of FZD7 in the survival, invasion
and metastatic capabilities of colon cancer cells with the use of
newly prepared and selected siRNAs against FZD7. Moreover, the
expression level of FZD7 mRNA was quantitatively evaluated in
primary CRC tissues (n¼ 135) to clarify whether it could be of
prognostic significance for CRC.
MATERIALS AND METHODS
Cell cultures
Human colon cancer cell lines, HCT-116 and HT-29, were
purchased from the ATCC (Manassas, VA, USA). Human
embryonic kidney 293T cells were purchased from RIKEN BRC
(Tsukuba, Japan). HCT-116 and HT-29 cells were cultured in
McCoy’s 5A medium (Gibco/Invitrogen, Carlsbad, CA, USA)
supplemented with 10% heat-inactivated fetal bovine serum,
100 IUml1 penicillin and 100 mgml1 streptomycin (Sigma,
St Louis, MO, USA). 293T cells were cultured in DMEM
(Nissui Pharmaceutical, Tokyo, Japan) supplemented with 10%
heat-inactivated fetal bovine serum (ATCC), 100 IUml1 penicillin
and 100mgml1 streptomycin (Sigma).
RNA interference
Small-interfering RNAs were constructed in the piGENE hU6
Vector (Clontech, Palo Alto, CA, USA). The nucleotide target
sequence for FZD7 were as follows: siRNA1 sequence, gcaccatcatga
aacacgacg; siRNA2 sequence, gcagacgtgcaagagctatgc; siRNA3
sequence, acctcttcataggcacgtcct; siRNA4 sequence, gttctcacctacctgg
tggac; siRNA5 sequence, ctgcagacgtgcaagagctat; siRNA6 sequence,
tacctgatgaccatgatcgtc; siRNA7 sequence, ctctgttcgtctacctcttcatagg;
siRNA8 sequence, gtcattctgtctctcacttggttcc; siRNA9 sequence, cctga
tgtactttaaggaggaggagag; siRNA10 sequence, gtaaagtgtacaagttacttt;
siRNA11 sequence, agcagtggtcaaaccataa; siRNA12 sequence, gaaggt
tgagaccagcagag; siRNA13 sequence, gggactgtgagcgatccccctgctgc;
EGFP siRNA sequence, ggctacgtccaggagcgcacc; scramble siRNA
sequence, gatcagcagctgacaacagtatcac. pcDNA3.1-U6EGFP_siRNA
and pcDNA3.1-U6FZD7_siRNA8 were obtained by subcloning
a EcoRI–HindIII fragment from piGENE-EGFP and piGENE-FZD7_
siRNA8 into the EcoRI–HindIII site of pcDNA3.1 (Invitrogen).
Luciferase reporter assay
For Tcf luciferase assays, cells were transfected with 0.475 mg
of TOPflash (Upstate, Lake Placid, NY, USA) and 0.025 mg of
pRL-TK Vector (Promega, Madison, WI, USA) according to the
manufacture’s instructions. The total amount of DNA was adjus-
ted to equal amounts with empty vector. At 48 h after transfection,
the luciferase levels were measured by using the Dual-Luciferase
Reporter Assay System (Promega). Data are presented as mean
values and s.d. for three independent experiments and compared
with the level of luciferase activity obtained in the presence of
EGFP_siRNA transfectant cells that is represented as 1.
Crystal violet stain
HT-29 and HCT-116 cells were transfected with plasmid by the
Nucleofector system (Amaxa, Cologne, Germany). Cells were
seeded in 2ml medium in a six-well tissue culture plate.
At 6 days after transduction, cells were stained with 0.5% crystal
violet in 20% methanol for 10min. Stable transfectants were
seeded at 104 cells per well in 2ml medium in a six-well tissue
culture plate. At 8 days after seeding, cells were stained with
0.5% crystal violet in 20% methanol for 10min. Cell viability was
determined by absorbance measurements at 595 nm using 2030
ARVO X4 (PerkinElmer, Boston, MA, USA).
Cell-cycle assay
HCT-116 cells were transfected with scramble siRNA or FZD7_
siRNA8. At 48 h after transfection, cells were harvested, fixed with
75% ethanol for 2 h at 41C, washed with phosphate-buffered saline
(PBS), treated with 100 mgml1 RNase (Sigma) for 30min at 371C
and stained in 10 mgml1 propidium iodide (Sigma) for 30min at
41C. Analysis was performed on Cytomics FC500 using FC500 CXP
Cytometer software (Beckman Coulter Co., Miami, FL, USA).
Western blot analysis and RhoA activation assay
At 48 h after transfection, cells were washed in ice-cold PBS and
re-suspended in cold buffer containing 1% Nonidet P-40, 0.5%
sodium deoxycholate, 0.1% SDS, 0.1mgml1 phenylmethyl
sulfonyl fluoride. Re-suspended cells were passed through the
21-gauge needle to shear the DNA and incubated for 60min on ice
followed by centrifugation at 10 000 g for 10min at 41C. Total
protein (10mg) was analysed by western blotting using primary
antibodies and anti-mouse and anti-rabbit IgG HRP-conjugated
secondary antibodies (Dako, Glostrup, Denmark), and were
visualised with LumiGLO Reagent and Peroxide (Cell Signaling
Technology, Beverly, MA, USA). Results of western blot analysis
were shown as ratio of band intensity, which indicates the ratio of
band intensity of tested protein to that of b-actin. Band intensity
was measured by using ImageJ software (NIH, Bethesda, MD,
USA). At 48 h after transfection, cells were assayed for Rho
activation with a Rho Activation Assay Kit (Upstate). The GTP-
bound fraction was monitored by western blot analysis. The
primary antibodies used were mouse anti-V5 (Invitrogen), anti-b-
actin (Abcam, Cambridge, UK), anti-p38, anti-phospho-p38, anti-
ERK, anti-phospho-ERK, anti-JNK, anti-phospho-JNK, anti-c-Jun
and anti-phosphor-c-Jun (BD Biosciences, San Jose, CA, USA)
monoclonal antibodies, and rabbit anti-RhoA monoclonal anti-
body (Cell Signaling Technology).
Cell invasion assay
Matrigel (1 : 5; BD Biosciences) was added to Transwell membrane
filter inserts (8.0mm pore size; Costar, Cambridge, MA, USA) and
incubated for 5 h at 371C in a 5% CO2 tissue culture incubator.
HCT-116 cells were transfected with scramble siRNA or FZD7_
siRNA8. At 24 h after transfection, cells were harvested and
re-suspended in serum-free medium. Aliquots (105 cells) of the
prepared cell suspension were added into the upper chamber and
the lower chamber was filled with 600ml of culture media
containing 5 mgml1 fibronectin (Sigma), as an adhesive substrate.
Cells were incubated for 48 h at 371C in a 5% CO2 tissue culture
incubator. Invasive cells were stained with Diff-Quick solution
(Fisher Scientific, Pittsburgh, PA, USA). Cells were counted with a
microscope. The average number of cells in five fields per
membrane was counted in triplicate.
Quantitative PCR
Total RNA was isolated from colon cancer cell lines and primary
colorectal tumour and non-tumour tissues using the RNeasy Plus
Mini Kit (Qiagen, Hilden, Germany) and All prep DNA/RNA
Mini kit (Qiagen), respectively. The extracted total RNA was
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reverse-transcribed into single-stranded cDNA using a High-
Capacity cDNA Archive Kit (Applied Biosystems, Warrington,
UK). Real-time PCR was performed using first-strand cDNA with
TaqMan Universal PCR Master Mix (Applied Biosystems). The
assay numbers for the endogenous control (b-actin) and target
genes were as follows: 4326315E (b-actin); Hs00275833_s1 (FZD7).
Quantitative PCR was performed on an ABI Prism 7900HT
Sequence Detection System (Applied Biosystems). Quantitative
PCR parameters for cycling were as follows: 501C for 2min hold,
951C for 10min 40 cycles of PCR at 951C for 15 s and 601C for
1min. All reactions were carried out in a 20-ml reaction volume in
triplicate. For target gene assays, total RNA was isolated from
colon cancer cell lines using the RNeasy Plus Mini Kit (Qiagen)
48 h after transfection. The extracted total RNA was reverse-
transcribed into single-stranded cDNA using High-Capacity cDNA
Archive Kit (Applied Biosystems). Real-time PCR was performed
using first-strand cDNA with Power SYBR Green PCR Master Mix
(Applied Biosystems). The primers used were as follows: FZD7
forward primer, 50-ttctcggacgatggctacc-30; FZD7 reverse primer,
50-gaaccaagtgagagacagaatgacc-30; CD44s forward primer, 50-tcataga
agggcacgtggtg-30; CD44s reverse primer, 50-tgggaggtgttggatgtgag-30;
CD44v6 forward primer, 50-cccagaaggaacagtggtttg-30; CD44v6
reverse primer, 50-agctgtccctgttgtcgaatg-30; CD44v8-9 forward
primer, 50-caggtttggtggaagatttgg-30; CD44v8-9 reverse primer,
50-tgtcagagtagaagttgttggatgg-30; Met forward primer, 50-caagaggag
ccccaccttatc-30; Met reverse primer, 50-ggcagtattcgggttgtaggag-30;
Survivin forward primer, 50-cggttgcgctttcctttc-30; Survivin reverse
primer, 50-tgttcttggctctttctctgtcc-30; MT1-MMP forward primer, 50-a
gattgatgctgctctcttctgg-30; MT1-MMP reverse primer, 50-tgccctgag
ctcttcgttg-30; Jun forward primer, 50-ggaaacgaccttctatgacgatg-30; Jun
reverse primer, 50-agggtcatgctctgtttcagg-30. Quantitative PCR was
performed on an ABI Prism 7900HT Sequence Detection System
(Applied Biosystems). Quantitative PCR parameters for cycling were
as follows: 951C for 10min 40 cycles of PCR at 951C for 15 s, and
601C for 1min. All reactions were carried out in a 20-ml reaction
volume in triplicate. The mRNA expression level was determined
using the 2DCT method.
Stable transfectants
pcDNA3.1-U6EGFP_siRNA or pcDNA3.1-U6FZD7_siRNA8 were
transfected into HCT-116 cells by FuGENE HD (Roche Diagnostics,
Basel, Switzerland). Stably transfected cells were selected 72 h
after transfection by neomycin resistance using G418 sulphate
(500mgml1; Sigma). G418-resistant colonies were cloned by
limiting dilution. The expression level of FZD7 mRNA in
transfectants was assayed by real-time PCR.
Liver metastasis in scid mouse
Transfectants were harvested, washed and then re-suspended in
serum-free McCoy’s 5A medium for injection. Scid mice were
injected with Nembutal as an anaesthetic, laid down dorsally and
an incision was made about 1 cm long above the spleen using a
surgical scissors. A cell suspension (2.5 106 per 100 ml) of
transfectants was injected into the spleen using a butterfly needle.
To arrest the flow of blood when the operator takes the needle out
of the spleen, we used an electric knife. The incision was then
sutured. Each animal group consisted of seven mice. Three weeks
after intrasplenal transplantation, mice were killed and the number
of metastatic foci in the liver was counted.
Primary colorectal cancer tissues and non-tumour tissues
FZD7 mRNA expression was measured in colorectal tumours
and non-tumour tissues obtained from 135 patients with CRC
after receiving informed consent. The experimental protocol was
approved by the institutional ethics committee of the Yamaguchi
University Graduate School of Medicine, Ube, Japan. The mean age
of patients was 67±11 (mean±s.d.) years, and consisted of both
men (70) and women (65). In all patients, the diagnosis of CRC was
made on the basis of endoscopic and histological findings.
A surgical operation was then carried out. The clinico-pathological
characteristics after surgery are shown in Table 1. From the entire
surgically resected tissue, viable tumour and non-tumour areas
were macroscopically judged and cut out by pathologists. The
tissues were immediately frozen in liquid nitrogen or subjected to
RNA isolation, which were then stored at 801C. For RNA storage,
RNAlater RNA Stabilization Reagent (Qiagen) was used.
Statistical analysis
The relationship of FZD7 mRNA levels with clinical stage and follow-
up information after surgery was analysed using the Kruskal–Wallis
and post hoc tests. Kaplan–Meier curves were compared using the
log-rank test. Data were processed using GraphPad Prism 5 software
(GraphPad Software, San Diego, CA, USA).
RESULTS
Preparation and selection of FZD7_siRNA
Thirteen shRNA expression vectors harbouring siRNAs against
FZD7 were constructed and tested to determine which had the
Table 1 Characteristics of colorectal cancer patients
All patients
(n¼ 135)
Selected
patientsa
(n¼121)
Age (years) (mean±s.d.) 66.9±11 66.4±11
Sex
Male 70 (52%) 64 (53%)
Female 65 (48%) 57 (47%)
pStage
I 14 (10%) 13 (11%)
II 51 (38%) 43 (35%)
III 42 (31%) 40 (33%)
IV 28 (21%) 25 (21%)
pT
is 1 (1%) 1 (1%)
1 7 (5%) 7 (6%)
2 9 (7%) 8 (6%)
3 105 (78%) 93 (77%)
4 13 (9%) 12 (10%)
pN
() 74 (55%) 63 (52%)
(+) 61 (45%) 58 (48%)
pM
() 108 (80%) 95 (79%)
(+) 27 (20%) 26 (21%)
Pathology
Moderately differentiated adenocarcinoma 81 (60%) 72 (60%)
Well-differentiated adenocarcinoma 42 (31%) 39 (32%)
Poorly differentiated adenocarcinoma 7 (5%) 6 (5%)
Mucinous adenocarcinoma 5 (4%) 4 (3%)
Abbreviations: pT¼ pathological tumor classification; pN¼ lymph node invasion;
pM¼ distant metastasis. aThe patients whose follow-up data were available.
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greatest suppressive effect on endogenous FZD7 expression in
colon cancer cells. Each shRNA expression vector was transfected
into HCT-116 cells and mRNA levels of FZD7 were examined
by real-time PCR (Figure 1A). The FZD7 expression in HCT-116
cells was reduced to 30% when using FZD7_siRNA8 compared to
a control siRNA. Therefore we used FZD7_siRNA8 as an FZD7_
siRNA for the following experiments.
To examine whether the FZD7_siRNA could discriminate
between FZD7 and FZD1 with the highest homology, we
co-transfected FZD7-V5 or FZD1-V5 and FZD7_siRNA into 293T
cells and subjected the whole proteins to immunoblotting with an
anti-V5 antibody (Figure 1B). The expression of FZD7-V5 protein
was abolished with FZD7_siRNA whereas that of FZD1-V5 was not.
Thus the FZD7_siRNA was used to specifically inhibit FZD7.
FZD7_siRNA suppressed cell viability and invasion
HCT-116 and HT-29 cells were transfected with scramble siRNA or
FZD7_siRNA, and the cells were stained with crystal violet stain 6
days after transfection. Viable cells were decreased to o10 and
40% in HT-29 and HCT-116 cultures, respectively (Figure 2A). On
the basis of this result and the fact that we were unable to isolate
stable HT-29 siRNA transfectants (see below), we used HCT-116
cells for the following siRNA transfection experiments.
To observe the effect of FZD7_siRNA on cell cycle, we
transfected HCT-116 cells with scramble siRNA or FZD7_siRNA,
and the cells were analysed by flow cytometry 48 h after
transfection. The percentage of cells at G2/M phase was reduced
from 40 to 30% with FZD7_siRNA transfection (Figure 2B). To
evaluate the effect of FZD7_siRNA on the expression and
activation of MAP kinases, we subjected HCT-116 cells transfected
with scramble siRNA or FZD7_siRNA to immunoblotting.
As shown in Figure 2C, the band intensities of c-Jun, p-JNK and
p-c-Jun were decreased by FZD7_siRNA.
JNK/c-Jun is involved in the non-canonical Wnt pathway and
is regulated by the small GTPase RhoA (Cohen et al, 2008). We
therefore examined whether FZD7_siRNA affects RhoA activation.
HCT-116 cells were transfected with scramble siRNA or FZD7_siRNA
and were subjected to the RhoA activation assay. As shown in
Figure 2D, FZD7_siRNA decreased RhoA activation. Because RhoA
has been shown to be involved in migration and dissemination of
colon cancer cells (Croft et al, 2004), we assessed, using the
Matrigel invasion assay, whether FZD7_siRNA affected the in vitro
invasion activity of HCT-116 (Figure 2E). The number of invading
cells was significantly decreased (Po0.0005) with FZD7_siRNA
transfection. To assess whether FZD7_siRNA indeed altered Wnt
target genes including invasion/metastasis-related ones, we
transfected FZD7_siRNA into HCT-116 cells and measured the
expression levels of mRNAs with real-time PCR. The transcrip-
tional levels of Wnt target genes including CD44v8-9 and MT1-
MMP were decreased with FZD7_siRNA (Figure 2F).
FZD7_siRNA inhibits in vivo metastasis
HCT-116 cells were transfected with pcDNA3.1-U6EGFP_siRNA or
pcDNA3.1-U6 FZD7_siRNA, and the expression level of FZD7 and
two target genes (MT1-MMP and Jun) in stable transfectants was
measured with real-time PCR. We used two stable transfectants
(FZD7_siRNA clone 1 and clone 2) that show the decreased
expression of these genes compared with control cells harbouring
EGFP_siRNA for the following experiments (Figure 3A). To test
canonical Wnt signal-transducing activity, we transfected TOP-
flash reporter plasmid into the transfectants, and measured the Tcf
transcriptional activity (Figure 3B). We found that Tcf activity was
decreased to B20% in both FZD7_siRNA clones compared to
control cells. Cell viability and invasion activity were also
significantly decreased in FZD7_siRNA transfectants (Po0.005
and o0.05, respectively; Figures 3C and D).
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Figure 1 Preparation and selection of FZD7_siRNA. (A) Real-time PCR analysis of FZD7 mRNA expression in HCT-116 cells transfected with shRNA
expression vectors harbouring siRNA against FZD7. Thirteen siRNAs were designed based on the nucleotide sequence of FZD7 gene. HCT-116 cells were
transiently transfected with shRNA expression vectors. At 48 h after transfection, total RNAs were reverse-transcribed and the levels of mRNA expression
of FZD7 were measured by real-time PCR. (B) FZD7_siRNA8 specifically inhibited the expression of FZD7. 293T cells were transiently transfected with
various combinations of pEF4, pEF4-FZD7-V5, pEF4-FZD1-V5, scramble RNA and FZD7_siRNA8. Cell lysates (10 mg) were analysed by western blotting
using anti-V5 or anti-b-actin antibodies.
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The anti-metastatic activity of FZD7_siRNA was also shown in
an in vivo liver metastasis model (Figure 3E). FZD7_siRNA
transfectants were transplanted into the spleen of scid mice, and
after 3 weeks, the mice were killed to count liver metastasis
colonies. Liver metastases in mice transplanted with FZD7_siRNA
transfectants were significantly decreased compared to the
EGFP_siRNA transfectants (Po0.05).
FZD7mRNA expression levels in primary colorectal
tumour tissues
The expression levels of FZD7 mRNA in 135 primary CRC and 38
non-tumour tissues were examined by real-time PCR. The clinico-
pathological characteristics of patients are shown in Table 1. FZD7
mRNA expression was significantly higher in the stage II, III or IV
tumour tissues than in non-tumour tissues (Po0.005; Figure 4A).
Follow-up information regarding survival was available for 121
patients. As shown in Table 1, there was no significant difference
in clinico-pathological characteristics between this patient group
(n¼ 121) and total patients (n¼ 135). The mRNA level of FZD7
was significantly higher in patients with recurrence or death after
surgery than in those with no recurrence (disease free) after
surgery (Po0.05; Figure 4B). Although there was no association
of FZD7 mRNA expression level with age, sex, tumour grade,
lymph node metastasis, distant metastasis or histological type
on univariate analysis (data not shown), higher FZD7 mRNA
expression (Xmean value of all tumours tested) was significantly
associated with shorter survival (Po0.001; Figure 4C).
DISCUSSION
Transient transfection of FZD7_siRNA prepared for this study into
colon cancer HCT-116 or HT-29 cells gave rise to a significant
suppression of cell viability (Figure 2A), confirming our previous
finding (Ueno et al, 2008). This also seems to be consistent with a
previous finding that siRNA inhibition of FZD7 decreased the
viability of mesenchymal stem cells (hMSCs; Song et al, 2006).
However, in contrast to this report, no apoptotic cells were
detected in our present experiments as well as in our previous
studies (Ueno et al, 2008). Although the mechanism is not fully
understood at present, the decrease of G2/M cells (Figure 2B)
suggests the involvement of the b-catenin/Tcf target genes c-myc
and cyclin-D (He et al, 1998; Tetsu and McCormick, 1999). Our
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Figure 2 FZD7_siRNA suppressed cell viability and invasion. (A) Effect of FZD7_siRNA on cell viability. HCT-116 and HT-29 cells were transiently
transfected with FZD7_siRNA or scramble siRNA control. At 6 days after transfection, HCT-116 and HT-29 cells were stained with crystal violet. Cell
viability was determined by absorbance at 595 nm. (B) Effect of FZD7_siRNA on cell cycle. HCT-116 cells were transfected with FZD7_siRNA or scramble
siRNA. Cells were harvested 48 h after transfection and cell-cycle analysis was performed using a Cytomics FC500 cell sorter. (C) Effect of FZD7_siRNA on
MAP kinase protein expression. HCT-116 cells were transiently transfected with FZD7_siRNA or scramble siRNA. At 48 h after transfection, cytosolic
protein (10 mg) was analysed. Expression of p38, phospho-p38, ERK, phosho-ERK, JNK, phospho-JNK, c-Jun or phospho-c-Jun was assessed by western blot
analysis. b-Actin was used as a loading control. Ratio of band intensity indicates the ratio of band intensity of tested protein to that of b-actin. Band intensity
was measured by using ImageJ software. (D) Effect of FZD7_siRNA on RhoA activation. HCT-116 cells were transfected with FZD7_siRNA or scramble
siRNA. At 48 h after transfection, GST-RhoA expression was assessed. Total RhoA was used as a loading control. Ratio of band intensity indicates the ratio
of band intensity of tested protein to that of b-actin. (E) Effect of FZD7_siRNA on cell invasion. HCT-116 cells were transiently transfected with
FZD7_siRNA or scramble siRNA. At 24 h after transfection, an aliquot (105 cells) of the prepared cell suspension was added into the upper chamber, the
lower chamber was filled with culture media containing fibronectin and cultured for 48 h. Invasive cells were stained and the average number of cells in five
fields per membrane was counted in triplicate. (F) Effect of FZD7_siRNA on Wnt target gene expression. HCT-116 cells were transiently transfected with
FZD7_siRNA or EGFP_siRNA. At 48 h after transfection, total RNAs were reverse-transcribed and the level of mRNA expression of Wnt target genes was
measured by real-time PCR.
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previous data demonstrated that the expression levels of c-myc
and cyclin-D mRNAs increased after FZD7 transfection into HCT-
116 cells and a siRNA against FZD7 suppressed c-Myc protein
expression (Ueno et al, 2008). Conversely, some Wnt signals were
shown to promote viability in some cell types (Almeida et al, 2005;
Railo et al, 2008). Wnt signalling through other FZDs might
protect our transfectants from apoptosis.
Western blot analyses for MAP kinases revealed that the
phosphorylation level of JNK was decreased whereas expression
and phosphorylation levels of other kinases were not (Figure 2C).
As expected from this result and the fact that c-jun is a Wnt
target gene (Mann et al, 1999), expression and phosphorylation of
c-Jun were also reduced (Figure 2C). A recent finding that RhoA
stimulates c-Jun expression through ROCK, which in turn activates
JNK (Marinissen et al, 2004), prompted us to examine RhoA
activation. As shown in Figure 2D, it was clearly decreased with
FZD7_siRNA transfection, suggesting that FZD7 may be a receptor
for the non-canonical Wnt/JNK signalling pathway in colon cancer
cells. These data may provide a molecular explanation for the
previous findings that inhibition of FZD7 expression decreased the
migratory activity of colon cancer cells (Vincan et al, 2007) and
hapatocellular carcinoma cells (Merle et al, 2004).
We have also demonstrated decreased invasion activity of
FZD7-down-regulated HCT-116 cells (Figure 2E). In addition
to migratory activity, proteolytic lysis of Matrigel is required for
cells to penetrate the membrane in the invasion assay we used.
The canonical Wnt pathway may be responsible for this process,
because it involves several extracellular proteinases such as
urokinase-type plasminogen activator (uPA) (Hiendlmeyer et al,
2004), uPA receptor (Mann et al, 1999), CD44 (Wielenga et al,
1999), matrix metalloproteinase (MMP)-7 (Brabletz et al, 1999)
and MT1-MMP/MMP-14 (Takahashi et al, 2002). It is also known
that the b-catenin/Tcf target gene fra-1 directly induces MMP-1
and MMP-9 promoter activity (Belguise et al, 2005). Our
quantitative RT-PCR data showed that the expression levels of
CD44v8-9 and MT1-MMP were decreased after FZD7_siRNA
transfection into HCT-116 cells (Figure 2F).
It remains to be determined how non-canonical Wnt signalling
interacts with the canonical Wnt/b-catenin/Tcf signalling in colon
cancer cells. It was shown that inhibitors of the canonical
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Figure 3 FZD7_siRNA inhibits in vivo metastasis. (A) The level of mRNA expression of FZD7, MT1-MMP and Jun in stable transfectants expressing
FZD7_siRNA. HCT-116 cells were transfected with shRNA-expressing vectors and stable transfectants were selected by neomycin resistance. The
expression levels of FZD7, MT1-MMP and Jun mRNAs in transfectants were assayed by real-time PCR. (B) Tcf-reporter transcriptional activity in
FZD7_siRNA transfectants. Stable transfectants were transiently co-transfected with TOPflash reporter plasmid and pRL-TK plasmid encoding Renilla
luciferase as an internal control for transfection efficiency. At 48 h after transfection, cell lysates were measured for relative luciferase activities. Data are
presented as mean values ±s.d. for three independent experiments and compared with the level of luciferase activity obtained in the presence of stable
transfectants expressing siRNA against EGFP that is represented as 1. (C) Cell viability of FZD7_siRNA transfectants. Stable transfectants were seeded at
104 cells per well in 2ml medium in a six-well tissue culture plate. At 8 days after seeding, cells were stained with crystal violet. Cell viability was determined
by absorbance measurements at 595 nm using 2030 ARVO  4 spectrophotometer. (D) Invasive ability of FZD7_siRNA transfectants. Aliquots (105 cells)
of the prepared cell suspension were added into the upper chamber and cultured into the lower chamber filled with culture media containing fibronectin for
48 h. Invasive cells were stained and the average number of cells in five fields per membrane was counted in triplicate assay. (E) In vivo metastatic ability of
FZD7_siRNA transfectants. Stable transfectants expressing FZD7_siRNA or EGFP_siRNA were injected into the spleen of scid mice. Three weeks after
transplantation mice were killed to count the number of liver metastasis.
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signalling, Dickkopf (DKK)-1 and a dominant-negative Tcf
construct, did not reduce Wnt3a-dependent motility of CHO-K1
cells (Endo et al, 2005), and that DKK-1 and DKK-2 had no
effect on Wnt3a-induced migration of myeloma cells (Weeraratna
et al, 2002). In the former cell model system, RhoA was
also activated with Wnt3a, whereas the activation of PKC
family proteins including PKCa, PKCb and PKCm as well as
RhoA was found in the latter. These findings suggest that cell
migration stimulated with Wnt may be independent of canonical
signalling.
We have shown that stable transfectants of HCT-116 cells
harbouring the FZD7_siRNA have decreased Tcf activity, viability
and invasion (Figures 3B–D), and less in vivo metastatic activity
using a liver metastasis model of HCT-116 cells in nude mice
(Bouvet et al, 2006). The number of metastatic foci with
FZD7_siRNA transfectants was significantly decreased compared
to that with control cells (Figure 3E). A major molecular basis for
this suppressive effect is thought to be due to the decreased
expression of motility- and invasion-related genes, but it is
possible that it partly reflects the reduced cell viability. As
described above, it was reported that FZD7 promotes cell survival
without altering cell proliferation in hMSCs (Song et al, 2006).
Furthermore, canonical Wnt signalling was shown to be involved
in the regulation of proliferation, as well as the migration/invasion
capacity of hMSCs (Neth et al, 2006). In this context, FZD7 might
be one of mesenchymal characteristics of colon cancer cells when
they metastasise through epithelial–mesenchymal transition
(Turley et al, 2008).
An important finding of this report is the prognostic signi-
ficance of FZD7 mRNA expression in primary CRC tissues. FZD7
expression was higher in the RecurrenceþDeath group than in the
Disease-free group (Figure 4D), and patients with higher FZD7
expression levels (Xmean of all cases) had worse overall survival
(Figure 4C). However, no association was found between FZD7
expression and clinico-pathological factors except for pathological
stage. This may be related to the functional diversity of FZD7
including induction of mesenchymal–epithelial transition (Vincan
et al, 2007), osteogenic differentiation of hMSCs (Song et al, 2006)
and Wnt11 induction of differentiated cell phenotypes (Yamanaka
and Nishida, 2007; Kim et al, 2008). We have detected Wnt11
mRNA in seven colon cancer cell lines (data not shown).
Nevertheless, our present clinical data support the importance of
FZD7 as a therapeutic target for CRC in those patients with higher
FZD7 expression.
In conclusion, we first reported that FZD7 may be impor-
tant in the survival, invasion and metastatic capabilities of
colon cancer cells, at least partly, through expression of c-Jun,
phosphorylation of c-Jun and JNK, and activation of
RhoA. Furthermore, higher expression levels of FZD7 mRNA in
primary CRC tissues were shown to be associated with poor
prognosis, suggesting that FZD7 may be involved in CRC
progression.
ACKNOWLEDGEMENTS
This study was supported by Grant-in-Aid for Scientific Research
on Priority Areas (no. 17016049) from the Ministry of Education,
Culture, Sports, Science and Technology, Japan (Y Hinoda).
P = 0.0015
P = 0.0001
P = 0.0004
n=38 n=14 n=51 n=42 n=28 n=79 n=42
Disease free Recurrence + DeathN I II III IV
P = 0.0116
R
el
at
iv
e 
ex
pr
es
sio
n
BA
R
el
at
iv
e 
ex
pr
es
sio
n
C
O
ve
ra
ll s
ur
viv
al
P = 0.0009
High n=12
Low n=109
1000
100
10
0.1
1
1000
100
10
0.1
1
100
100 150
Low
High80
40
60
0
0
20
50
Time (month)
Figure 4 The expression level of FZD7 mRNA in primary colorectal tumour and non-tumour tissues. (A) Comparison of tumour with non-tumour
tissues. The mRNA levels of FZD7 in primary colorectal tumour and non-tumour tissues were examined by real-time PCR. Tumours were divided
into four groups according to the pathological stage (see Table 1). (B) Effect of clinical course after surgery on FZD7 expression level. Patients were
divided into disease free after surgery and recurrence or death after surgery groups according to the follow-up information after surgery. Disease free
indicated a patient group with no recurrence after surgery. RecurrenceþDeath indicated a patient group with recurrence or death after surgery.
(C) Kaplan–Meier analysis for overall survival of patients. High or low indicates the patients with the FZD7 mRNA levelsX oro the mean value (11.1) of
all tumours tested.
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